Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06673667 · ClinicalTrials.gov registry record · Phase 1

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

A Phase 1 study, sponsored by Kymera Therapeutics.

Completed
Registry status
Phase 1
Development phase
118
Enrollment target

NCT06673667: Completed Phase 1 study, sponsored by Kymera Therapeutics.

NCT06673667 is a Phase 1 study that has completed, run by Kymera Therapeutics. The registered enrollment target is 118 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06673667, a Phase 1 study, has completed, sponsored by Kymera Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
118 participants
Enrollment target

Study Summary

This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.

Interventions

  • DRUG Placebo
  • DRUG KT-621

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2024-10-22
Est. Completion 2025-04-23
Phase Phase 1
Kymera Therapeutics

10 total trials

What the finished NCT06673667 record still lists

NCT06673667 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06673667 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06673667 about?

NCT06673667 is a clinical study titled "First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants". This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.

What is the current status of trial NCT06673667?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2024-10-22. Estimated completion is 2025-04-23.

What interventions are being tested in trial NCT06673667?

The interventions under investigation include: Placebo (DRUG), KT-621 (DRUG).

Who is sponsoring clinical trial NCT06673667?

This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06673667's enrollment target sits among peer trials

118 499th of 2000 higher than 1,502 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821623 · 118 participants · Phase 2

    Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

  • NCT04040959 · 118 participants · Phase 2

    Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

  • NCT04696029 · 118 participants · Phase 2

    DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  • NCT05223192 · 118 participants · NA

    The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06673667, the US trial registry maintained by the National Library of Medicine. NCT06673667 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.